武汉大学人民医院湖北省人民医院

院内导航

易欣心内
副教授，副主任医师，硕士生导师

A+ A-

导师介绍

姓名	易欣
出生年月	1987/4/18
单位	武汉大学人民医院心血管内科
所属学科	临床医学-内科学
职务、职称及头衔	副教授，副主任医师，硕士生导师
E-mail	yixin321624@126.com
联系方式	13349896619
研究方向	1.心脏重构与表观遗传调控 2.心肌缺血再灌注损伤与表观遗传调控
个人简介	主要从事心血管疾病的临床与科研工作，主持国家自然科学基金、湖北省自然科学基金、湖北省卫生健康委员会科研项目等8项，荣获”武汉大学人民医院第五轮青年重点培养对象“。以第一、通讯作者发表论文50余篇，其中SCI论文25篇，包括Pharmacol Res、Cell Death & Disease、Cell Prolif、Clinical Epigenetics等。
学术任职与荣誉	欧美同学会（中国留学人员联谊会）医师协会大血管疾病分会宣传部副主任 Traditional Medicine Research青年编委中国医药教育协会医疗器械管理专业委员会心血管分会委员 Oxidative Medicine and Cellular Longevity特邀编辑 Oncology、International Journal of Molecular Medicine、Molecular Medicine Reports、Experimental and Therapeutic Medicine审稿专家
教育履历	2005.09-2010.06承德医学院临床医学专业本科生获学士学位 2010.09-2015.06武汉大学第一临床学院内科学博士研究生获博士学位 2013.09-2015.03美国德克萨斯农工大学健康医学中心联合培养博士研究生
工作履历	2015.07-2015.11 武汉大学人民医院心血管内科住院医师 2015.11-2017.11 武汉大学人民医院心血管内科主治医师 2017.11-至今武汉大学人民医院心血管内科副主任医师 2023.05-至今武汉大学人民医院心血管内科副教授
成果获奖	无
代表性论著	1.Fang ZM, Zhang SM, Luo H, Jiang DS, Huo B, Zhong X, Feng X, Cheng W, Chen Y, Feng G, Wu X, Zhao F,Yi X. Methyltransferase-like 3 suppresses phenotypic switching of vascular smooth muscle cells by activating autophagosome formation. Cell Prolif. 2022 Dec 23:e13386.（共同通讯） 2. Li J, Jiang XJ, Wang QH, Wu XL, Qu Z, Song T, Wan WG, Zheng XX,Yi X. Data-independent acquisition proteomics reveals circulating biomarkers of coronary chronic total occlusion in humans. Front Cardiovasc Med. 2022 Dec 5;9:960105. （通讯作者） 3.Chen Y,Yi X, Huo B, He Y, Guo X, Zhang Z, Zhong X, Feng X, Fang ZM, Zhu XH, Wei X, Jiang DS. BRD4770 functions as a novel ferroptosis inhibitor to protect against aortic dissection. Pharmacol Res. 2022 Mar;177:106122.（共同第一） 4.Yi X, Zhou Y, Chen Y, Feng X, Liu C, Jiang D-S, Geng J, Li X, Jiang X, Fang Z-M.The Expression Patterns and Roles of Lysyl Oxidases in Aortic Dissection. Front. Cardiovasc. Med. 2021;8:692856. 5. Wei X,Yi X, Zhu XH, Jiang DS. Posttranslational Modifications in Ferroptosis. Oxid Med Cell Longev. 2020 Nov 26;2020:8832043. (共同第一) 6. Wei X,Yi X, Zhu XH, Jiang DS. Histone methylation and vascular biology. Clin Epigenetics. 2020 Feb 18; 12(1):30. (共同第一) 7.Yi X, Jiang XJ, Fang ZM. Histone methyltransferase SMYD2: ubiquitous regulator of disease. Clin Epigenetics. 2019 Aug 1; 11(1):112. 8. Li R,Yi X, Wei X, Huo B, Guo X, Cheng C, Fang ZM, Wang J, Feng X, Zheng P, Su YS, Masau JF, Zhu XH, Jiang DS.EZH2 inhibits autophagic cell death of aortic vascular smooth muscle cells to affect aortic dissection. Cell Death Dis. 2018 Feb 7; 9(2):180. (共同第一) 9.Yi X, Tao Y, Lin X, Dai Y, Yang T, Yue X, Jiang X, Li X, Jiang DS, Andrade KC, Chang J. Histone methyltransferase Setd2 is critical for the proliferation and differentiation of myoblasts. Biochim Biophys Acta Mol Cell Res. 2017 Apr;1864(4): 697-707.

Name	XIN YI
Date of birth	April, 1987
Department	Cardiovascular Department, Renmin Hospital of Wuhan University
Title	Aassociate professor, Aassociate chief physician, master tutor
Email	yixin321624@126.com
TEL	13349896619
Research Direction	1. Cardiac remodeling and epigenetic regulation 2. Myocardial ischemia reperfusion injury and epigenetic regulation
Personal Profile	She is mainly engaged in the diagnosis and treatment of cardiovascular diseases,and has been awarded 8 grants from the National Natural Science Foundation, the Natural Science Foundation of Hubei Province, the Health Commission of Hubei Province. She was awarded the Key Youth Training Objects of the Fifth Round of Renmin Hospital of Wuhan University. Besides,there are 50 articles published by the first author and corresponding author, including 25 SCI papers in Cell Death & Disease, Clinical Epigenetics, etc..
Selected Publications	1.Fang ZM, Zhang SM, Luo H, Jiang DS, Huo B, Zhong X, Feng X, Cheng W, Chen Y, Feng G, Wu X, Zhao F,Yi X. Methyltransferase-like 3 suppresses phenotypic switching of vascular smooth muscle cells by activating autophagosome formation. Cell Prolif. 2022 Dec 23:e13386.（共同通讯） 2. Li J, Jiang XJ, Wang QH, Wu XL, Qu Z, Song T, Wan WG, Zheng XX,Yi X. Data-independent acquisition proteomics reveals circulating biomarkers of coronary chronic total occlusion in humans. Front Cardiovasc Med. 2022 Dec 5;9:960105. （通讯作者） 3.Chen Y,Yi X, Huo B, He Y, Guo X, Zhang Z, Zhong X, Feng X, Fang ZM, Zhu XH, Wei X, Jiang DS. BRD4770 functions as a novel ferroptosis inhibitor to protect against aortic dissection. Pharmacol Res. 2022 Mar;177:106122.（共同第一） 4.Yi X, Zhou Y, Chen Y, Feng X, Liu C, Jiang D-S, Geng J, Li X, Jiang X, Fang Z-M.The Expression Patterns and Roles of Lysyl Oxidases in Aortic Dissection. Front. Cardiovasc. Med. 2021;8:692856. 5. Wei X,Yi X, Zhu XH, Jiang DS. Posttranslational Modifications in Ferroptosis. Oxid Med Cell Longev. 2020 Nov 26;2020:8832043. (共同第一) 6. Wei X,Yi X, Zhu XH, Jiang DS. Histone methylation and vascular biology. Clin Epigenetics. 2020 Feb 18; 12(1):30. (共同第一) 7.Yi X, Jiang XJ, Fang ZM. Histone methyltransferase SMYD2: ubiquitous regulator of disease. Clin Epigenetics. 2019 Aug 1; 11(1):112. 8. Li R,Yi X, Wei X, Huo B, Guo X, Cheng C, Fang ZM, Wang J, Feng X, Zheng P, Su YS, Masau JF, Zhu XH, Jiang DS.EZH2 inhibits autophagic cell death of aortic vascular smooth muscle cells to affect aortic dissection. Cell Death Dis. 2018 Feb 7; 9(2):180. (共同第一) 9.Yi X, Tao Y, Lin X, Dai Y, Yang T, Yue X, Jiang X, Li X, Jiang DS, Andrade KC, Chang J. Histone methyltransferase Setd2 is critical for the proliferation and differentiation of myoblasts. Biochim Biophys Acta Mol Cell Res. 2017 Apr;1864(4): 697-707.